Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at...
CUPERTINO, Calif.,, June 02, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...
CUPERTINO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...
- Hosted key opinion leader (KOL) webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders led by industry thought leaders Leslie...
CUPERTINO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...
Virtual event on Tuesday, May 3rd at 10:00 AM ET An overview of unmet medical needs and therapeutic opportunities in schizophrenia and major...
CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage...
CUPERTINO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...
- 5th Annual Neuroscience Innovation Forum - - BIO-Europe Spring® 2022 - CUPERTINO, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals...
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 - $29.7 Million in Cash as of...